Doctors, pharmacists, and managed care executives in the US want important changes to the pharmaceutical industry in 2016 — including lower drug prices for patients, greater pharmacy reimbursement, and an expanded focus on patient-centered care.
That’s the assessment made in a statement provided Monday morning to mHealthWatch from InCrowd.
However they were strongly pessimistic about whether these changes will happen, according to new data compiled by InCrowd, a provider of real-time market intelligence to life sciences and healthcare firms. The results document the frustration within key constituencies in the pharma industry following a year of controversy over drug price hikes, M&A deals, patent protection via data exclusivity windows, and Presidential candidate proposals for expanded industry oversight.
“The discrepancy between what the industry wants, and what it thinks it will get, is stark,” said Diane Hayes, PhD, president and co-founder of InCrowd. “Over half of respondents expected the exact opposite result of what they hoped to get, like wanting lower drug prices, and expecting there would be no change at all.”
InCrowd asked members of its Crowd of 1.8 million of clinicians, pharmacy staff, and managed care providers, about important changes and innovations they wanted to see in the pharmaceutical industry in 2016 — and at the same time, what changes they realistically expected.